Oliver Luxxe Assets LLC Has $5.21 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Oliver Luxxe Assets LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,958 shares of the medical research company’s stock after buying an additional 44 shares during the quarter. Thermo Fisher Scientific accounts for about 1.1% of Oliver Luxxe Assets LLC’s holdings, making the stock its 29th biggest position. Oliver Luxxe Assets LLC’s holdings in Thermo Fisher Scientific were worth $5,207,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Diversified Trust Co raised its holdings in shares of Thermo Fisher Scientific by 3.2% during the 1st quarter. Diversified Trust Co now owns 8,976 shares of the medical research company’s stock valued at $5,217,000 after purchasing an additional 282 shares in the last quarter. Aviance Capital Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 20.9% during the 1st quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock valued at $7,581,000 after purchasing an additional 2,251 shares in the last quarter. Roberts Wealth Advisors LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $4,422,000. Financial Partners Group LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $241,000. Finally, Blue Zone Wealth Advisors LLC grew its stake in Thermo Fisher Scientific by 2.1% in the 1st quarter. Blue Zone Wealth Advisors LLC now owns 9,651 shares of the medical research company’s stock valued at $5,609,000 after buying an additional 198 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 2.1 %

Shares of TMO traded down $11.49 on Monday, reaching $541.51. 639,749 shares of the company’s stock were exchanged, compared to its average volume of 1,544,296. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $206.71 billion, a P/E ratio of 35.47, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. The business has a 50 day moving average price of $574.84 and a two-hundred day moving average price of $563.36. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,000 shares of company stock worth $12,532,780. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. Barclays decreased their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday. Evercore ISI raised their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Finally, Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $607.06.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.